



**HFS**

Illinois Department of  
Healthcare and Family Services

JB Pritzker, Governor

201 South Grand Avenue East, Springfield, Illinois 62763

Theresa A. Eagleson, Director

Telephone: +1 217-782-1200, TTY: +1 800-526-5812

**Illinois Drug Utilization Review  
Board Meeting Minutes  
October 26, 2023**

**I. Call to Order, Roll Call**


- a. Call to order
  - i. Meeting conducted via a Webex webinar format.
  - ii. The meeting was recorded in accordance with the Open Meetings Act. Guests wishing to speak during public comment were requested to type name and affiliation in the Webex Chat. Phone-in attendees instructed to email Jen DeWitt with full name, title, and affiliation.
  - iii. Dr. Schriever called the meeting to order at 8:30am.
- b. Roll call
  - i. Roll call was taken and a quorum was established. Present: Drs. Schriever, Sreedhar, Ahluwalia, An, Aziz, Nikocecic, Stevens. Not present: Dr. Wheat

**II. Agenda, conflict of interest review, and approval of July 27, 2023 meeting minutes**

- a. No DUR Board members had conflicts of interest pertinent to the agenda. Dr. Schriever reminded DUR Board members to recuse themselves from discussion if conflicts of interest are present and to provide an updated *Conflict of Interest* form if new conflicts arise.
- b. October 26, 2023 meeting agenda and July 27, 2023 meeting minutes- No changes or additions. Motion to approve both made by Dr. An, seconded by Dr. Stevens.
- c. Vote: In favor- 7; Against- 0; Abstentions- 0. July 27, 2023 meeting minutes approved.

**III. Board Updates**

- a. Board member annual training
  - i. Training modules need to be completed by the end of 2023 for existing members.
  - ii. Pending creation of profiles by Bureau of Training for Drs. Aziz and Wheat.
- b. Dr. Ihab Aziz, MD and Dr. Santana Wheat, MD were approved by the Director as new members of the DUR Board.
- c. DUR Bylaws
  - i. New DUR Bylaws will be created by an ad hoc committee of Board members.
  - ii. Board members interested in this committee were asked to indicate so in the chat or contact Claudia Colombo via email.
- d. 2024 Chairperson and Vice-Chairperson nominations
  - i. Dr. Erica Stevens nominated for Chairperson by Dr. Schriever. Seconded by Dr. Nikocecic.
  - ii. Dr. Schriever nominated himself for Vice-Chairperson. Seconded by Dr. Sreedhar.
  - iii. Dr. Nikocecic moved to close the nomination. Seconded by Dr. Schriever.
  - iv. Motion made by Dr. Schriever for Dr. Stevens to serve as Chairperson in 2024.
  - v. Vote: In favor- 7; Against- 0, Abstentions- 0.
  - vi. Motion made by Dr. Schriever for himself to serve as Vice-Chairperson in 2024.
  - vii. Vote: In favor- 7; Against- 0, Abstentions- 0.



**HFS**

Illinois Department of  
Healthcare and Family Services

JB Pritzker, Governor

201 South Grand Avenue East, Springfield, Illinois 62763

Theresa A. Eagleson, Director

Telephone: +1 217-782-1200, TTY: +1 800-526-5812

- IV. Quarterly Reports** – presented by Maurice Shaw, PharmD
- a. Top 10 spend Fee-For-Service (FFS) drugs (2023Q3)
  - b. Top 10 script count FFS- Prescription only (2023Q3)
  - c. Top 10 script count FFS- OTC only (2023Q3)
  - d. Top 5 script count by disease state: Diabetes (FFS and Managed Care Organization (MCO), 2023Q2)
    - i. Board suggested investigating glipizide prescribing.
  - e. Top 5 script count by disease state: Hypertension (FFS and MCO, 2023Q2)
    - i. Board suggested investigating prazosin and hydralazine utilization and diagnosis.
  - f. Top 5 script count by disease state: Depression (FFS and MCO, 2023Q2)
  - g. Top 5 script count by disease state: Asthma (FFS and MCO, 2023Q2)
- V. Retrospective DUR**
- a. RetroDUR 300 follow-up – Presented by Christina Petrykiw, PharmD, CDCES
    - i. Study 34 had 126 FFS participants with 730 RetroDur issues with 29 issues warranting outreach to provider.
    - ii. Study 35 had 107 FFS participants with 631 RetroDur issues with 32 issues warranting outreach.
    - iii. Issues warranting outreach (Total issues= 61)
      - a. Daily dose issues= 23
      - b. Duplicate therapy= 20
      - c. Drug interaction= 1
      - d. Pharmacist identified issue= 17
    - iv. Outcomes
      - a. Therapy changed= 20, re-evaluation= 10, dose/medication appropriate based on new information= 14, insurance/eligibility/provider change= 4, calls/recommendations made, provider to confirm next step= 11
    - v. Two participant cases highlighting QT prolongation with mental health medications and respective outreach results were presented.
    - vi. Discussion
      - a. Retrospective review and education for high albuterol use in chronic obstructive pulmonary disease (COPD) with or without asthma. Education regarding the current guidelines and evidence-based treatments for concomitant asthma and COPD.
      - b. Academic Detailing was highlighted as an effective way to communicate with providers.
      - c. Prescriber education about QT prolongation risk and monitoring.
      - d. High-dose edit- perphenazine.
        - a. Edit would require a review by a pharmacist before dispensing.
      - e. Motion made to review doses of perphenazine exceeding 36mg per day made by Dr. Sreedhar. Seconded by Dr. An.
      - f. Vote: In favor- 7; Against- 0, Abstentions- 0.
  - b. Single-ingredient buprenorphine prescribing – Presented by Maurice Shaw, PharmD
    - i. Department of Justice (DOJ) targeted intervention of medications for opioid use disorder (MOUD)
      - a. Buprenorphine plus concurrent therapy with either benzodiazepines, stimulants, central nervous system (CNS) depressants, or opioids
      - b. Single-ingredient buprenorphine- chronic use. Monitor prescribers with greater than 10% single-ingredient buprenorphine prescriptions.



**HFS**

Illinois Department of  
Healthcare and Family Services

JB Pritzker, Governor

201 South Grand Avenue East, Springfield, Illinois 62763

Theresa A. Eagleson, Director

Telephone: +1 217-782-1200, TTY: +1 800-526-5812

- ii. Data run and analysis presented. Six-month time frame reviewed (1-1-2023 to 6-30-2023)
  - a. Board members had no comments.

**VI. Prospective DUR – Presented by Maurice Shaw, PharmD**

- a. Naloxone/opioid prescribing
  - i. Illinois legislation requires that prescribers shall offer a prescription for naloxone, or another similar drug approved by the Food and Drug Administration (FDA) under specified circumstances: 1) Patient’s MME is 50 or more morphine milligram equivalents (MME) per day. 2) An opioid medication prescribed concurrently with a benzodiazepine, or 3) The patient has an increased risk for overdose, known history of substance use disorder, or is at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.
  - ii. Data run and analysis.
    - a. Identified participants who had a claim for an opioid prescription from 1/1/2023 to 6/30/2023. Medication profiles were reviewed back two years to 1/1/2021 to determine how many participants that had a claim for an opioid also had a claim for an opioid reversal agent.
    - b. Fee-for-service patients: 4.7% of participants had a naloxone claim.
    - c. Managed care organization (MCO): 9.6% of participants had a naloxone claim.
  - iii. Discussion
    - a. Motion to approach commonly used medical informatics systems in Illinois (i.e., EPIC) to add an edit to prescribe naloxone when 50 MME is exceeded made by Dr. Sreedhar. Seconded by Dr. Nikocevic.
    - b. Vote: In favor- 7; Against- 0, Abstentions- 0.


**VII. Public Comments – No public comments were made.**

**VIII. Announcements – Claudia Colombo, PharmD**

- a. Proposed 2024 DUR Board Meeting dates. Time: 8:30am – 10:30am.
  - i. Thursday, January 25, 2024
  - ii. Thursday, April 25, 2024
  - iii. Thursday, August 8, 2024
  - iv. Thursday, October 31, 2024
- b. Motion to approve proposed 2024 DUR Board Meeting dates made by Dr. Aziz. Seconded by Dr. Sreedhar.
- c. Vote: In favor- 7; Against- 0, Abstentions- 0.
- d. Vote to continue conducting meetings via Webex webinar.
- e. Motion to continue conducting meetings via Webex webinar made by Dr. An. Seconded by Dr. Nikocevic.
- f. Vote: In favor- 7; Against- 0, Abstentions- 0.

**IX. Department Updates – Jose Jimenez, Bureau of Professional and Ancillary Services Bureau Chief**

- a. Synagis: Healthcare and Family Services (HFS) has released a Provider Notice regarding an October 1, 2023 start to the Synagis season. Prior authorization staff have been receiving and processing requests. The MCOs have been instructed to follow FFS direction to start the season early.
- b. Beyfortus: Beyfortus, when available, will be supplied by the Vaccines for Children (VFC) program.



**HFS**

Illinois Department of  
Healthcare and Family Services

JB Pritzker, Governor

201 South Grand Avenue East, Springfield, Illinois 62763

Theresa A. Eagleson, Director

Telephone: +1 217-782-1200, TTY: +1 800-526-5812

- c. D&T Board updates: D&T Board recommended at their October 5, 2023 meeting that HFS cover the GLP1-RA class for weight loss. HFS is currently in the process of updating our State Plan Amendment (SPA) so that weight loss medications can be covered. Guidance will be released in the future, pending CMS approval of the SPA.
- d. Leadership changes: Director Theresa Eagleson is leaving HFS at the end of 2023.

**X. Adjournment**

- a. Next DUR Board Meeting- Thursday, January 25, 2024, 8:30am – 10:30am
- b. Motion made to adjourn the meeting at 9:53am by Dr. Sreedhar. Seconded by Dr. An.
- c. Vote: In favor- 7; Against- 0; Abstentions- 0. Meeting adjourned.

**Meeting Attendance**

DUR Board Members

Christopher Schriever, PharmD, MS, AAHIVP, Chair

Radhika Sreedhar, MD, MS, FACP, Vice-Chair

Aneet Ahluwalia, MD

Sam An, PharmD

Ihab Aziz, MD, ABFM, FAAFP

Bedrija Nikocecic, PharmD, BCACP

Erica Stevens, PharmD, BCGP

Staff/Panelists

Donna Clay, BSP Pharm – UIC

Claudia Colombo, PharmD – UIC Springfield

Melissa Davis – BPAS

Jen DeWitt, BSP Pharm – UIC Springfield

Sheri Dolan, BSP Pharm – UIC Springfield

Thomas Dorn, PharmD – UIC

Heather Freeman – BPAS

Arvind Goyal, MD, MPH, MBA - Medical Director, HFS

Jose Jimenez, Bureau Chief – BPAS

Debra Long – BPAS

Mary Moody, BSP Pharm – UIC

Christina Petrykiw, PharmD, CDCES – UIC

Maurice Shaw, PharmD – UIC Springfield

Guests/Attendees

Tammy Bima

Kimbra Brooks

Kevin Hall

Kelly Hamilton

Janie Huff

Clemice Hurst

Doug Johnson

Phil Lohec

Neelesh Nadkarni

Keith O'Hara



**HFS**

Illinois Department of  
Healthcare and Family Services

JB Pritzker, Governor

201 South Grand Avenue East, Springfield, Illinois 62763

Theresa A. Eagleson, Director

Telephone: +1 217-782-1200, TTY: +1 800-526-5812

Nichole Palusinski

Gary Parenteau

Kelly Petroski

Kenneth Ring

Ryan Segroves

Michele Shirley

Chase Williams

Call-in User 2 (217558\*\*\*\*)

Call-in User 3 (630805\*\*\*\*)

Call-In User 4 (262339\*\*\*\*)

**Approved January 25, 2024 by the Illinois Drug Utilization Review Board**